BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MiMedx (MDXG)MiMedxEarnings

MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026.

Related news

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-04-22 12:00 EST

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

RXRXRecursion2026-07-29 12:30 EST

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-11-06 13:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-10-28 20:03 EST

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-10-28 20:01 EST

MIMEDX Announces $25 Million Patent License Agreement

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MDXGMiMedx2026-09-23 20:01 EST

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Stock data

Close
3.28 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States